Ventus stops Phase 2 of NLRP3 inhibitor that was being tested in Parkinson’s

Ventus Therapeutics has terminated a Phase 2a trial of an NLRP3 inhibitor, an en vogue class with broad potential in neurology, obesity and other areas. The drug, VENT-02, was being tested ...